Meeting
2024 ASCO Genitourinary Cancers Symposium
Optimal timing of delayed cytoreductive nephrectomy in metastatic renal cell carcinoma during the immunotherapy era.
Authors
Insija Ilyas Selene
University of Kentucky, Lexington, KY
Insija Ilyas Selene , Feitong Lei , Bin Huang , Amina Dhahri , Patrick Heckman , Roshmita Bardhan , Jemin Jose , Zin Myint
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 403)
DOI
10.1200/JCO.2024.42.4_suppl.403
Abstract #
403
Poster Bd #
G6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the National Cancer Database (NCDB).
First Author: Maroun Bou Zerdan
Poster
2019 ASCO Annual Meeting
Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib.
First Author: Bimal Bhindi
Poster
2024 ASCO Genitourinary Cancers Symposium
Effect of cytoreductive nephrectomy on the efficacy of immunotherapy in metastatic renal cell carcinoma by decreasing IL-6 to modulate tumor-associated macrophage and myeloid-derived suppressor cell.
First Author: Jee Soo Park
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of timing of immunotherapy and cytoreductive nephrectomy on outcomes in metastatic renal cell carcinoma: Results from the CKCis database.
First Author: Changsu Park